FimmCyte AG

First Disease Modifying Treatment for Endometriosis

One in 10 women suffer from Endometriosis: a painful, chronic, infertility causing and recurrent disease. Endometriosis has a physical health burden comparable to cancer, yet only one new treatment was approved for it in the past decade. An unacceptable state given the inadequacy of current treatments which are only palliative, with countless side effects. Endometriosis' burden reverberates through the healthcare system, economy, and society with millions of women suffering and billions of direct and indirect costs. To address this unmet medical need, we engineered a first-in-class treatment that has shown efficacy in eliminating endometriosis tissue in the lab and animal models which we aim to bring to the clinic in the next few years and give women back control of their body.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No milestones

No Jobs

No videos and documents

TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

Website

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Website

Venture Leaders Biotech

FimmCyte AG

First Disease Modifying Treatment for Endometriosis

Headquarter:
Basel

Foundation Date:
January 2022

Technology:

  • Biotech

Sectors:

  • Biotech

Support received

  • Support venture leaders
  • Support venturekick
  • Support TOP 100